Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

atigue; AEs were consistent in severity and frequency to historical Peg-IFN/RBV treatment. There were no clinically significant, treatment-emergent trends in any clinical laboratory parameters.  

PSI-7977 with Peg-IFN/RBV resulted in rapid viral suppression, with all HCV GT2 or 3 patients (n=24) achieving both a rapid virologic response (RVR) and remaining below the limit of detection through the end of treatment at week 12 (EOT). No patient exhibited viral breakthrough. These HCV GT2 or 3 patients are now being monitored for an additional 24 weeks to assess SVR at 12 weeks (SVR12) and 24 weeks (SVR24) after the discontinuation of therapy. Initial data have been submitted for presentation at an upcoming major scientific conference scheduled to take place during the first half of 2011.

In addition to the ongoing Phase 2b dose-ranging study, we recently announced the initiation of an exploratory Phase 2 study of PSI-7977 and RBV with 0-12 weeks of interferon in patients with HCV GT2 or GT3.  During the second quarter of 2011, we also expect to initiate a 24-week Phase 2b study of PSI-7977 with Peg-IFN/RBV.

PSI-938In late November 2010, we initiated Part 2 of a Phase 1 study that includes the first combination of a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for the treatment of HCV. The cohorts within Part 2 are evaluating PSI-938 300mg QD as monotherapy and in combination with PSI-7977 400mg QD. The primary objective is to assess the safety, tolerability and pharmacokinetics of PSI-938 alone and in combination with PSI-7977. The secondary objective of Part 2 is to evaluate the short-term change in HCV RNA.

Preliminary results with PSI-938 300mg QD administered as monotherapy for 14 days demonstrate:

  • PSI-938 was generally safe and well tolerated over 14 days
  • There were no serious adverse events, and no dose modifications or discontinuations
  • There were no clinically significan
    '/>"/>

  • SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
    3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
    4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
    5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
    6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
    7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
    8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
    9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
    10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
    11. Pharmasset Receives Notice of Allowance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 2014  ProteinSimple announced today that it has launched ... assay allows users to detect all proteins separated in ... users can analyze proteins without the need for an ... protein analysis as we know it today. First, the Simple ... no messy gels, no transfer tanks, no blots, no ...
    (Date:7/28/2014)... Germany and LONDON ... , Collaboration aims to create and commercialize ... guide the use of IRESSA  for non-small cell lung ... on QIAGEN,s FDA-approved  therascreen   EGFR test and is planned ... automated instruments  Project enabled by AstraZeneca master ...
    (Date:7/28/2014)... 28, 2014 OmPrompt today ... to help it meet the global demand for ... and logistics. Albion joins Shackleton Ventures. ... Over the past 18 months OmPrompt has underpinned ... management team and its operations. The new funding ...
    Breaking Medicine Technology:ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6OmPrompt Funded for Customer Automation Management Market Expansion 2
    (Date:7/28/2014)... 2014 Thousands of DePuy Pinnacle hip ... individuals who were allegedly injured by a metal-on-metal version ... forward in U.S. District Court, Northern District of Texas, ... on July 18, 2014, U.S. District Judge Ed Kinkeade ... Plaintiffs’ Steering Committee that sought the deposition of a ...
    (Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
    (Date:7/28/2014)... (PRWEB) July 28, 2014 Ticket Down ... Colombia tickets in Miami, FL at the Sun Life ... South American football between Argentina and Brazil has is one ... stronger worldwide, more rivalries are forming on a consistent basis. ... reached a new height in the recent 2014 World Cup. ...
    (Date:7/28/2014)... 2014 (HealthDay News) --,The more chronic medical conditions people ... may be, a new study claims. Since ... issues, scientists at Johns Hopkins Bloomberg School of Public ... why gains in life expectancy are slowing in the ... as diabetes, kidney disease and heart failure is now ...
    (Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
    Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2
    ... COLUMBUS, Ohio Chronic inhalation of polluted air appears ... white blood cells, setting off events that lead to ... model. This finding narrows the gap in researchers, ... the risk for cardiovascular problems and other diseases. ...
    ... Jeremy M. Berg, Ph.D., director of the National ... Institutes of Health (NIH), and Norman P. Neureiter, Ph.D., ... the American Association for the Advancement of Science (AAAS), ... Service Award for their vision and leadership in science ...
    ... way of discovering a gene,s function is to switch it ... an organism. If a gene is essential for survival, however, ... the gene,s function can be determined. Researchers at Cold Spring ... interference (RNAi) technology to temporarily turn off any essential gene ...
    ... release is available in French . Montreal, ... treat tics in Tourette syndrome may be as effective as ... a new study published in a special edition of the ... Research Centre of the Louis-H. Lafontaine Hospital affiliated with Universit ...
    ... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) ... in controlling and containing the spread of potentially lethal ... one study showed that certain interventions could decrease transmissions ... the other found no improvement when a somewhat different ...
    ... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) -- The ... to a decade before symptoms appear, a new study finds. ... Massachusetts General Hospital in Boston did brain imaging tests on ... the 33 people in the Mass General group, eight developed ...
    Cached Medicine News:Health News:Polluted air leads to disease by promoting widespread inflammation 2Health News:Polluted air leads to disease by promoting widespread inflammation 3Health News:Polluted air leads to disease by promoting widespread inflammation 4Health News:Polluted air leads to disease by promoting widespread inflammation 5Health News:American Chemical Society honors Jeremy Berg and Norman Neureiter with Public Service Award 2Health News:American Chemical Society honors Jeremy Berg and Norman Neureiter with Public Service Award 3Health News:CSHL team perfects non-lethal way of switching off essential genes in mice 2Health News:CSHL team perfects non-lethal way of switching off essential genes in mice 3Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 3Health News:Brain May Shrink in Decade Before Alzheimer's Symptoms Appear 2Health News:Brain May Shrink in Decade Before Alzheimer's Symptoms Appear 3Health News:Brain May Shrink in Decade Before Alzheimer's Symptoms Appear 4
    IRMA kit for detection of the cardiac marker Myoglobin...
    ... The assay is an immunometric ... measurement of Prolactin in human ... the sample is bound by ... different epitopes. One antibody is ...
    ... Immunosorbent Assay (ELISA) serves the quantitative,determination of ... serum and,urine. In a 1 hour incubation ... bound to an,available excess of polyclonal rabbit ... surface of the microtitre plates. After a ...
    ... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
    Medicine Products: